Liminatus Pharma, Inc. (NASDAQ: LIMN) Enters MOU with Capital Trust Group for $30 Million Equity Investment Through Earn-Out Structure and Future Strategic Partnership
Liminatus Pharma's MOU with CTG: Liminatus Pharma has signed a Memorandum of Understanding with Capital Trust Group for a USD 30 million equity financing to support its immunotherapy research and development.
Investment Details: The investment is contingent on due diligence and the negotiation of definitive agreements, with plans to finalize these agreements in November 2025.
Future Cooperation: Alongside the equity investment, discussions for further strategic cooperation, including potential digital bond financing programs, are set to begin in mid-November.
Company Background: Liminatus Pharma focuses on developing next-generation immuno-oncology therapies, while CTG is a New Zealand-based investment management firm involved in large-scale financing across various sectors.
Trade with 70% Backtested Accuracy
Analyst Views on LIMN
About LIMN
About the author

- Significant Transaction Value: Etsy has entered into a definitive agreement with eBay to sell its fashion marketplace Depop for approximately $1.2 billion in cash, which not only provides Etsy with substantial cash flow but also enhances its financial flexibility to support future strategic investments.
- Stock Price Surge: Etsy's shares jumped 15.5% to $50.86 in pre-market trading, reflecting a positive market reaction to the deal and increasing investor confidence in the company's future growth potential.
- Market Consolidation Trend: This transaction signifies further consolidation in the e-commerce sector, as eBay's acquisition of Depop will expand its influence in the fashion market, while Etsy can focus on its core business to improve operational efficiency.
- Strategic Focus Shift: By selling Depop, Etsy can reallocate resources to concentrate on growth within its primary platform, with expectations to drive long-term profitability through optimizing product lines and enhancing user experience.
- Market Performance: U.S. stocks traded mostly lower on Tuesday, with the Nasdaq Composite falling over 50 points, and the S&P 500 dropping 0.13% to 6,827.16, indicating a cautious investor sentiment amid market weakness.
- Company Highlights: Medtronic PLC (NYSE:MDT) reported an adjusted EPS of $1.36 for Q3, exceeding market expectations of $1.33, with quarterly sales of $9.017 billion surpassing the $8.905 billion forecast, showcasing the company's strong earnings capability.
- Sector Dynamics: Financial shares gained 0.9%, while materials stocks fell by 2%, reflecting a divergence in market performance as investors may be seeking more defensive investment opportunities amidst volatility.
- Economic Indicators: According to ADP Research, U.S. private employers added an average of 10,250 jobs per week during the four weeks ending January 31, up from 7,750 in the previous period, indicating an improving labor market trend.
- Dow Jones Index Gains: On Tuesday, the Dow Jones index rose approximately 0.1%, trading up 0.06% to 49,529.45 points after the market opened, indicating a mild optimistic sentiment despite mixed overall performance.
- NASDAQ and S&P 500 Performance: The NASDAQ fell 0.03% to 22,540.83 points, while the S&P 500 gained 0.04% to 6,838.63 points, reflecting a divergence between tech stocks and blue-chip stocks, prompting investors to monitor sector dynamics closely.
- Manufacturing Index Decline: The NY Empire State Manufacturing Index dropped to 7.1 in February from 7.7 in January and below the market estimate of 7, indicating a slowdown in manufacturing activity that could impact overall economic growth expectations.
- Improved Employment Data: According to ADP Research, U.S. private employers added an average of 10,250 jobs per week during the four weeks ending January 31, compared to 7,750 in the prior period, suggesting a gradual recovery in the labor market.
- Revenue Guidance Increase: Credo Technology expects to report revenue between $404 million and $408 million, significantly up from prior guidance of $335 million to $345 million, indicating strong market demand and business growth potential.
- Significant Year-over-Year Growth: The company anticipates over 200% year-over-year growth in the current fiscal year, reflecting its competitive position in the industry and rapid market share expansion.
- Quarterly Growth Outlook: Credo also expects mid-single-digit sequential revenue growth to round out the year, suggesting continued strong performance in the coming months, which enhances investor confidence.
- Positive Stock Reaction: In pre-market trading, Credo Technology shares jumped 17.4% to $144.87, reflecting market optimism regarding its financial outlook and potentially attracting more investor interest.
- Earnings Beat: Super Micro Computer reported Q2 earnings of $0.69 per share, surpassing the analyst consensus of $0.49 by 41.68%, indicating a significant improvement in profitability that boosts investor confidence.
- Significant Revenue Growth: The quarterly revenue reached $12.68 billion, exceeding the market estimate of $10.22 billion and representing a 123.76% increase from $5.68 billion in the same period last year, showcasing the company's strong market performance and growth potential.
- Optimistic Outlook: Super Micro expects Q3 adjusted EPS of $0.60, above the analyst estimate of $0.53, and anticipates revenue in the range of $12.3 billion to $12.6 billion, reflecting confidence in future performance.
- Positive Stock Reaction: In pre-market trading, Super Micro's shares jumped 10.5% to $32.79, indicating a favorable market response to its strong earnings and optimistic outlook.
- Earnings Surprise: Teradyne's fourth-quarter earnings report exceeded market expectations on both revenue and earnings per share, leading to a 22.2% surge in pre-market trading to $305.00, indicating strong investor confidence in its financial performance.
- Optimistic Outlook: The company forecasts first-quarter adjusted EPS between $1.89 and $2.25, significantly above the analyst estimate of $1.24, showcasing robust profitability and market demand.
- Revenue Projections Raised: Teradyne anticipates first-quarter revenue in the range of $1.15 billion to $1.25 billion, well above the analyst expectation of $927.72 million, reflecting the company's competitive edge and growth potential in the market.
- Positive Market Reaction: The substantial increase in stock price not only reflects investor approval of the company's performance but may also attract more institutional investors, potentially driving further stock price appreciation.









